Why Most Women Never Start Hormone Therapy
Part 1 of the Menopause Care Series: the access gap, the fear, and the appointments that send women home with nothing
Why women aren't offered hormone therapy
There is a particular kind of tired that shows up in my office. It isn't only the 3 a.m. wake-ups or the hot flashes that arrive in the middle of a meeting. It is the tiredness of having already asked for help, sometimes more than once, and being told some version of that's just part of getting older.
Many of the women I work with in perimenopause and menopause have never been offered hormone therapy. Some were told they were too young to be in perimenopause, even though symptoms can start in the late 30s and early 40s. Some were told their labs were "normal" (as if a single estradiol level on a random day could capture a transition defined by fluctuation). Some were told hormones cause breast cancer, full stop, and that was the end of the conversation. And many never asked at all, because somewhere along the way they absorbed the idea that suffering through it quietly was the responsible thing to do.
This is the first article in a three-part series on menopause care. Part 2 looks at why some women on hormone therapy still don't feel like themselves, and Part 3 covers non-hormonal support for women who can't or don't want to use hormones. But I wanted to start here, with the women who never get to the point of choosing, because that is where the biggest gap is.
To be clear up front: this isn't an article telling every woman she should be on hormone therapy. Menopausal hormone therapy (MHT) is a medical decision with real benefits and real risks, and it isn't right for everyone. What I am saying is that every woman deserves an informed conversation about it, with accurate information and a clinician who takes her symptoms seriously. Right now, most women aren't getting that conversation.
How many women use menopause hormone therapy?
You may have seen the claim that 80% of women never start hormone therapy. I went looking for the study behind that number and couldn't find a single source that supports it as stated, so I'm not going to repeat it here. The real numbers tell the story well enough on their own.
Hormone therapy use collapsed and never recovered. Among postmenopausal women in the US, use of hormone therapy fell from about 27% in 1999 to roughly 5% by early 2020, according to a 2024 analysis of national survey data published in JAMA Health Forum. That drop began in 2002, with the first results from the Women's Health Initiative (more on that below), and it kept sliding for nearly two decades.
Most women with significant symptoms go untreated. A large Yale analysis of insurance claims from more than 500,000 women found that while about 60% of women with significant menopause symptoms sought medical care, nearly three-quarters of them were left untreated.
Put those numbers side by side and the picture is sobering. It isn't that women aren't asking. Many are. It is that the system they're asking often doesn't have a good answer for them.
And the stakes aren't small. Up to 80% of women experience hot flashes and night sweats during the menopause transition, and for some they last a decade or longer. (That is likely where the "80%" figure got tangled up: it is a real number, just not about hormone therapy.) Add in disrupted sleep, mood changes, brain fog, joint pain, vaginal dryness and painful sex, bone loss, and shifts in cardiovascular and metabolic risk, and you are looking at years of a woman's life, often her peak working and caregiving years, lived at less than full capacity.
There are three big reasons women never start, and they usually overlap: access, fear, and the appointment itself.
Why many doctors aren't trained in menopause care
Here is something most women don't know: the doctor you see for your annual exam may have received very little training in menopause.
A survey of OB-GYN residency programs found that only about 20% offered formal menopause training, and nearly 80% of residents said they felt "barely comfortable" discussing or treating menopause. A 2023 survey from The Menopause Society found that just 31% of OB-GYN residency program directors reported having a menopause curriculum, and about 84% said they wanted more resources to teach it.
If that is the picture in OB-GYN, the specialty most focused on women's reproductive health, you can imagine what it looks like in family medicine and internal medicine, where most women actually get their care. This isn't a criticism of individual clinicians, many of whom are doing their best inside a system that gives them 15 minutes and very little training. It is a structural gap, and women are the ones who fall into it.
Access has other layers, too:
Time. Menopause care takes a real conversation: symptom history, personal and family risk factors, preferences, follow-up. That is hard to fit into a visit that's also covering a Pap smear, a refill, and a mammogram order.
Cost and coverage. Some formulations aren't covered, or are covered only after a woman has "failed" a different option first. Specialist and menopause-focused care is often out of network.
Geography. Certified menopause practitioners are unevenly distributed, and many women live hours from one.
Who gets believed. Research on pain and symptom reporting has repeatedly shown that women, and especially women of color, are more likely to have their symptoms minimized. Menopause care is not immune to that.
The result is a kind of quiet triage, where the women who get good menopause care are often the ones with the time, money, knowledge, and persistence to go looking for it. That shouldn't be the entry fee.
Is hormone therapy safe? What the WHI study really found
If you were an adult in 2002, you may remember the headlines. The Women's Health Initiative (WHI), a large federally funded trial, stopped its estrogen-plus-progestin arm early and reported increased risks of breast cancer, heart attack, stroke, and blood clots. Almost overnight, millions of women stopped their hormones, and a generation of clinicians learned to treat hormone therapy as something dangerous.
The WHI was an important study. But the way its results were communicated left out a lot of context, and that context matters:
The women were older than the women who usually start MHT. The average participant was 63, many were more than a decade past their final period, and many already had risk factors for heart disease. Most women considering hormone therapy are in their 40s and early 50s.
Relative risk sounded scarier than absolute risk. The widely reported "26% increase" in breast cancer translated to roughly 8 additional cases per 10,000 women per year on combined estrogen and synthetic progestin. That isn't nothing, but it is a very different number to sit with.
The estrogen-only arm told a different story. In women without a uterus who took estrogen alone, long-term follow-up actually showed fewer breast cancer diagnoses and deaths compared with placebo.
Timing turned out to matter. Later analyses supported what is often called the "timing hypothesis": for healthy women who start hormone therapy before age 60 or within 10 years of menopause, the benefits generally outweigh the risks. This is the position of The Menopause Society's 2022 hormone therapy statement.
Formulation and route matter, too. The WHI used one oral estrogen (conjugated equine estrogens) and one synthetic progestin (medroxyprogesterone acetate). Transdermal estradiol (patches, gels, sprays) does not appear to raise blood clot risk the way oral estrogen does in observational research, and micronized progesterone may carry a different risk profile than synthetic progestins. These differences are still being studied, but they are real enough that "hormone therapy" is no longer one thing.
In November 2025, the FDA announced it would remove the boxed "black box" warnings from estrogen-containing hormone therapy products, with new labeling that reflects age and timing. The boxed warning for endometrial cancer remains on systemic estrogen-only products, which is why women who still have a uterus need a progestogen alongside estrogen. Many menopause experts had been asking for this change for years, because the warnings scared away women who were good candidates.
None of this means hormone therapy is risk-free, or that every woman should take it. Women with a history of estrogen-sensitive breast cancer, certain clotting disorders, active liver disease, unexplained vaginal bleeding, or a history of stroke or heart attack need a much more careful conversation, and for some, hormones aren't an option at all (that is Part 3). But it does mean the fear many women carry is based on an incomplete, 20-year-old version of the story.
How to talk to your doctor about hormone therapy
Access and fear are the big structural reasons. But for a lot of women, the moment that actually closes the door is a single appointment.
It often sounds like one of these:
"Your labs are normal."
"You're too young for menopause."
"It's probably stress. Have you tried exercising more?"
"Let's start you on an antidepressant and see how you feel."
"Hormones cause cancer, so that's not something I prescribe."
Some of these contain a grain of truth. Stress really does affect symptoms, and antidepressants are a legitimate option for some women (they show up in Part 3). But when they're used to end the conversation instead of open it, women walk out feeling unheard, and many of them don't come back.
A few things are worth knowing before your next visit:
Perimenopause is mostly a clinical diagnosis. For women over 45, guidelines generally recommend diagnosing perimenopause and menopause based on symptoms and cycle changes, not blood tests. Hormone levels swing widely in perimenopause, so a "normal" estradiol or FSH on one day doesn't rule anything out. Labs are still useful for ruling out other causes, such as thyroid disease, iron deficiency, or blood sugar problems, which is part of why a good workup matters.
Perimenopause can start earlier than you think. Symptoms commonly begin in the early to mid-40s, and sometimes the late 30s. Irregular cycles, new sleep trouble, heavier or closer-together periods, worsening PMS, anxiety that seems to come from nowhere, and night sweats around your period are all worth bringing up.
You can ask for what you want to discuss. It is completely reasonable to say, "I'd like to talk about whether hormone therapy is an option for me, including the risks and benefits for my specific history." If your clinician isn't comfortable having that conversation, it is also reasonable to ask for a referral to someone who is.
How to prepare for the appointment
Track your symptoms for 1 to 3 months. Note sleep, hot flashes or night sweats, mood, cycle changes, joint pain, brain fog, libido, and vaginal or urinary symptoms. Patterns are much more persuasive than "I just don't feel like myself."
Write down your top three priorities. What is affecting your life most? Lead with that.
Know your personal and family history. Breast cancer, blood clots, stroke, heart disease, osteoporosis, and liver disease all shape the conversation.
Bring your questions in writing. For example: Am I a candidate for hormone therapy? Which type, dose, and route would you suggest, and why? What are my specific risks? What would we monitor? If not hormones, what else?
Ask about the menopause-trained clinicians in your area. The Menopause Society keeps a searchable directory of certified practitioners.
And if you leave an appointment feeling dismissed, that isn't a verdict on whether your symptoms are real. It is a sign you need a different clinician, not a different body.
You deserve the whole conversation
I think about the women who never start more than almost anyone else in this work. Not because hormones are the answer for all of them, but because so many of them never got to decide. The decision got made for them, by a 2002 headline, a rushed appointment, a lack of training they had no way of knowing about, or a quiet belief that this is simply what women are supposed to endure.
You are allowed to want more than endurance.
You are allowed to ask questions, to bring a list, to get a second opinion, and to expect a clinician who looks at your whole picture: your symptoms, your history, your risks, your goals, and your preferences. You are allowed to decide that hormone therapy is right for you, and you are allowed to decide that it isn't. Either way, the choice should be yours, made with good information.
And whichever way you go, hormones are rarely the whole answer. Blood sugar, gut health, sleep, nutrients, and a nervous system that has been running on empty for years all shape how this transition feels. That is where the next two articles go: Part 2 looks at why some women on hormone therapy still feel off, and Part 3 covers non-hormonal support for women who can't or don't want to use hormones.
If you'd like support working through this with someone who will actually listen, you can book a consult or learn about my group program, Transforming (peri)Menopause.
Chelsie Moore, MS, CNS, LDN, is a functional medicine clinician and integrative nutritionist at Moore Integrative Health in Portland, Oregon.
This article is for educational purposes only and is not medical advice. Hormone therapy and its alternatives involve individual risks and benefits. Please talk with a qualified healthcare provider about your personal health history before starting, stopping, or changing any treatment.
Sources
Yang L, Toriola AT. Menopausal hormone therapy use among postmenopausal women. JAMA Health Forum. 2024. Reported in JAMA: Use of menopausal hormone therapy dropped sharply
AARP. Most women with menopause symptoms go untreated (summarizing the Yale claims analysis and residency training data)
Contemporary OB/GYN. Survey shows menopause curriculums lacking in residency programs (2023 Menopause Society survey)
Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
Chlebowski RT, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. 2020;324(4):369–380.
The North American Menopause Society. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767–794.
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
U.S. Food and Drug Administration. HHS advances women's health, removes misleading FDA warnings on hormone replacement therapy. November 2025.
Harvard Health Publishing. FDA removes menopause hormone therapy black box warnings
Avis NE, et al. Duration of menopausal vasomotor symptoms over the menopause transition (SWAN). JAMA Internal Medicine. 2015;175(4):531–539.
National Institute for Health and Care Excellence. Menopause: identification and management (NG23)